Protagonist Therapeutics (PTGX) Long-Term Debt Issuances (2019 - 2023)

Protagonist Therapeutics (PTGX) has 4 years of Long-Term Debt Issuances data on file, last reported at $24.3 million in Q1 2023.

• For the quarter ending Q1 2023, Long-Term Debt Issuances rose 66.99% year-over-year to $24.3 million; the trailing twelve-month figure through Dec 2023 stood at $24.3 million (up 66.99% YoY), and the FY2023 full-year result was $24.3 million, up 66.99% from the prior year.
• Long-Term Debt Issuances advanced to $24.3 million in Q1 2023, from $14.6 million in the prior quarter.
• In the past five years, Long-Term Debt Issuances ranged from a high of $34.0 million in Q3 2019 to a low of -$24.7 million in Q4 2019.
• A 4-year average of $12.2 million and a median of $16.7 million in 2020 frame the typical range for Long-Term Debt Issuances.
• Peak annual rise in Long-Term Debt Issuances reached 176.2% in 2020, while the deepest fall reached 81.23% in 2020.
• Tracing PTGX's Long-Term Debt Issuances over 4 years: stood at -$24.7 million in 2019, then jumped by 176.2% to $18.8 million in 2020, then declined by 22.77% to $14.6 million in 2022, then jumped by 66.99% to $24.3 million in 2023.
• Business Quant data shows PTGX's Long-Term Debt Issuances at $24.3 million in Q1 2023, $14.6 million in Q1 2022, and $18.8 million in Q4 2020.